Jack Lasersohn Insider Buy
The Oncomed Pharmaceuticals Inc’s director Jack Lasersohn bought - 13,140 shares of Oncomed Pharmaceuticals Inc, based on the stock price per share of $14.6 for each one share. The company’s shares not a long ago had a value of around $191,784 US Dollars. This shares transaction occurred on September 30, 2015 and was that was filed with the Security and Exchange Commission. The source filing is free at your disposal here. The regulatory filing shows that Jack Lasersohn now has in hand about 6.67% of the California-based company’s market capitalization (total value of the shares outstanding)
Oncomed Pharmaceuticals Inc Sentiment and Fundamentals
In addition, the five leading equity analysts that are in charge of Oncomed Pharmaceuticals Inc, see $-2.03 earnings for each share in 2015. This will give it Price to Earnings ratio of around NaN & growth rate YOY of 0.00%-plus.
Based on Jack’s trade but in disagreement with our momentum system as shown below, we rate Oncomed Pharmaceuticals Inc’s stock as “Neutral”. Oncomed Pharmaceuticals Inc’s stock price chart indicates it has dived 16.08% in the last 200 days and the undeniable down trend is expected to continue.
Institutional Ownership
According to SEC filings for Q2 2015, 77 hedge funds and institutional investors own Oncomed Pharmaceuticals Inc. In Q2 2015, Oncomed Pharmaceuticals Inc had 28.62% institutional ownership. That is a high interest. Its up 8.71% from previous quarter. These institutional and hedge funds increased the total shares they own by 689,449 to 8.60 million this quarter. A total of 12 funds opened new positions in Oncomed Pharmaceuticals Inc and 42 increased their holdings. There were 7 funds that closed their positions and 13 that reduced them.
Hodges Capital Management Inc. is the most positive institutional investor on Oncomed Pharmaceuticals Inc, with ownership of 25,000 shares as of Q2 2015 for 0.02% of the fund’s portfolio. Bvf Inc Il is another positive investment manager possessing 1.26 million shares of the company or 5.02% of their stocks portfolio. The stock is also 2.85% of the fund’s AUM. The Vermont-based fund Birchview Capital Lp have 0.71% of their stock portfolio invested in the company’s market cap for 58,689 shares. In addition, The Quebec - Canada-based fund Sectoral Asset Management Inc revealed it had acquired a stake worth 1.29% of the fund’s stock portfolio in the company. The California-based fund Apex Capital Llc was also a notable believer in the company, possessing 388,100 shares. Oncomed Pharmaceuticals Inc is 0.76% of the fund’s stock portfolio.
Oncomed Pharmaceuticals NASDAQ:OMED Firm Profile
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing protein therapeutics targeting cancer stem cells (CSCs). The Company’s product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. Its technology is used to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation, and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company is also engaged in discovering multiple product candidates that target fundamental biological pathways in immuno-oncology. Its products include Demcizumab, AntiDLL4/VEGF bispecific, Tarextumab, AntiNotch1, Vantictumab, Ipafricept, Wnt 3rd Biologic, Wnt Small Molecules and AntiRSPO.
Company Website: Oncomed Pharmaceuticals
As of writing its market worth is: $498.71 million and it has 34.32 million shares outstanding. Currently there are 36.93% shareholders and the institutional ownership is 36.93%. This company has 108 employees. Oncomed Pharmaceuticals Inc was incorporated in Delaware on 2004-07-19. The stock closed at $16.59 yesterday and it had average 2 days volume of 104777 shares. It is up from the 30 days average shares volume of 61925. Oncomed Pharmaceuticals Inc has a 52weeks low of $14.03 and a 52 weeks high of $29.83. The current price is below the 200 days Simple moving average. Oncomed Pharmaceuticals Inc last issued its quarterly earnings stats on 08/10/2015. The company reported -0.72 EPS for the quarter, above the consensus estimate of -0.76 by 0.04. The company had a revenue of 4.69 million for 6/30/2015 and 9.69 million for 3/31/2015. Therefore, the revenue was -5,000,000 down.
Jack Lasersohn is also director of Masimo Corp, Metabolix, Inc., Kyphon Inc, Alus Liquidation Corp.
* The shares are held by Vertical Fund I - L.P. - a Delaware limited partnership (“VFI”). The Vertical Group - L.P. - a Delaware limited partnership - is the sole general partner of VFI - and The Vertical Group GP - LLC controls The Vertical Group - L.P. Mr. Lasersohn is a Member and Manager of The Vertical Group GP - LLC. All shares of stock indicated as owned by Mr. Lasersohn are included because of his affiliation with The Vertical Group - L.P. Mr. Lasersohn disclaims beneficial ownership of all securities that may be deemed to be beneficially owned by The Vertical Group - L.P. - except to the extent of any pecuniary interest therein. This Form 4 shall not be deemed an admission that Mr. Lasersohn or any other person referred to herein is a beneficial owner of any securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.
* The shares are held by Vertical Fund II - L.P. - a Delaware limited partnership (“VFII”). The Vertical Group - L.P. - a Delaware limited partnership - is the sole general partner of VFII - and The Vertical Group GP - LLC controls The Vertical Group - L.P. Mr. Lasersohn is a Member and Manager of The Vertical Group GP - LLC. All shares of stock indicated as owned by Mr. Lasersohn are included because of his affiliation with The Vertical Group - L.P. Mr. Lasersohn disclaims beneficial ownership of all securities that may be deemed to be beneficially owned by The Vertical Group - L.P. - except to the extent of any pecuniary interest therein. This Form 4 shall not be deemed an admission that Mr. Lasersohn or any other person referred to herein is a beneficial owner of any securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.
